Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection

Danis N., TÖZ H., ÜNAL N. G., YILMAZ M., TURAN İ., Gunsar F., ...More

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.8, pp.695-701, 2019 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 8
  • Publication Date: 2019
  • Doi Number: 10.5152/tjg.2019.18833
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.695-701
  • Keywords: Paritaprevir, ritonavir, ombitasvir, dasabuvir, renal transplant, hepatitis C, ANTIVIRAL THERAPY, RECIPIENTS, EFFICACY, IMPACT, SAFETY
  • Dokuz Eylül University Affiliated: No


Background/Aims: The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease. Most of our renal transplant (RT) recipients were treated with PrOD. The aim of the present study was to investigate the efficacy and safety of PrOD in RT patients with hepatitis C virus (HCV) infection in a single center real-life experience.